{"id":7963,"date":"2021-04-01T08:21:27","date_gmt":"2021-04-01T07:21:27","guid":{"rendered":"https:\/\/www.archimedlife.com\/lyso-gl-3-gb3-fabry-biomarker-associated-with-adverse-clinical-outcomes\/"},"modified":"2021-04-01T08:21:27","modified_gmt":"2021-04-01T07:21:27","slug":"lyso-gl-3-gb3-fabry-biomarker-associated-with-adverse-clinical-outcomes","status":"publish","type":"post","link":"https:\/\/www.archimedlife.com\/es\/lyso-gl-3-gb3-fabry-biomarker-associated-with-adverse-clinical-outcomes\/","title":{"rendered":"Lyso-GL-3: An important Fabry biomarker associated with adverse clinical outcomes"},"content":{"rendered":"\n

Biomarkers in Rare Diseases<\/a> play a dual and significant role in supporting improved clinical outcomes. In Fabry Disease<\/a> (FD), the glycosphingolipid globotriaosylceramide (Gb3\/GL-3) and its deacylated derivative globotriaosylsphingosine (Lyso-Gb3\/Lyso-GL-3) accumulate in different body parts and Lyso-GL-3 is considered the hallmark biomarker for this disease.1<\/sup><\/p>\n\n\n\n

Earlier works have shown that Lyso-GL-3 analysis is an important indicator for identifying Fabry Disease, in particular for females with FD<\/a> where enzyme activity testing is typically normal. In a recent publication in the Journal of Medical Genetics, Novak et al show that Lyso-GL-3 is a significant risk factor associated with adverse clinical events such as kidney replacement, atrial fibrillation, or cerebrovascular events. <\/p>\n\n\n\n

“A specific biomarker could not only fill the diagnostic gap but also improve disease staging and risk stratification as well as support the decision whether a patient should be started on ERT and or if he should be more closely monitored.”<\/p><\/blockquote>\n\n\n\n

In this paper, Novak explains that Lyso-GL-3 levels do decrease initially with enzyme replacement therapy however in some patients (e.g. with antidrug antibodies), the levels of Lyso-GL-3 will begin to rise again over time. This highlights the importance of measuring biomarker levels during disease diagnosis, prior to treatment initiation, and continually monitoring biomarker levels during treatment.<\/p>\n\n\n\n

Read the entire paper at the Journal of Medical Genetics<\/a>.<\/p>\n\n\n\n

References<\/strong>
[1] Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008;105:2812\u20137.doi:10.1073\/pnas.0712309105pmid:http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18287059<\/p>\n","protected":false},"excerpt":{"rendered":"

Biomarkers in Rare Diseases play a dual and significant role in supporting improved clinical outcomes. In Fabry Disease (FD), the glycosphingolipid globotriaosylceramide (Gb3\/GL-3) and its…<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[129,128],"tags":[136,137],"yoast_head":"\nLyso-GL-3: An important Fabry biomarker associated with adverse clinical outcomes - ARCHIMEDlife<\/title>\n<meta name=\"description\" content=\"Learn more about Lyso-GL-3: An important Fabry biomarker associated with adverse clinical outcomes in our Publications section.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.archimedlife.com\/es\/lyso-gl-3-gb3-fabry-biomarker-associated-with-adverse-clinical-outcomes\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lyso-GL-3: An important Fabry biomarker associated with adverse clinical outcomes - ARCHIMEDlife\" \/>\n<meta property=\"og:description\" content=\"Learn more about Lyso-GL-3: An important Fabry biomarker associated with adverse clinical outcomes in our Publications section.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.archimedlife.com\/es\/lyso-gl-3-gb3-fabry-biomarker-associated-with-adverse-clinical-outcomes\/\" \/>\n<meta property=\"og:site_name\" content=\"ARCHIMEDlife\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T07:21:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.archimedlife.com\/wp-content\/uploads\/2021\/01\/logo-drop-200x200-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\">\n\t<meta name=\"twitter:data1\" content=\"1 minuto\">\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.archimedlife.com\/#website\",\"url\":\"https:\/\/www.archimedlife.com\/\",\"name\":\"ARCHIMEDlife\",\"description\":\"Medical Laboratory\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/www.archimedlife.com\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.archimedlife.com\/es\/lyso-gl-3-gb3-fabry-biomarker-associated-with-adverse-clinical-outcomes\/#webpage\",\"url\":\"https:\/\/www.archimedlife.com\/es\/lyso-gl-3-gb3-fabry-biomarker-associated-with-adverse-clinical-outcomes\/\",\"name\":\"Lyso-GL-3: An important Fabry biomarker associated with adverse clinical outcomes - ARCHIMEDlife\",\"isPartOf\":{\"@id\":\"https:\/\/www.archimedlife.com\/#website\"},\"datePublished\":\"2021-04-01T07:21:27+00:00\",\"dateModified\":\"2021-04-01T07:21:27+00:00\",\"author\":{\"@id\":\"https:\/\/www.archimedlife.com\/#\/schema\/person\/28191618190aca02326147911e870968\"},\"description\":\"Learn more about Lyso-GL-3: An important Fabry biomarker associated with adverse clinical outcomes in our Publications section.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.archimedlife.com\/es\/lyso-gl-3-gb3-fabry-biomarker-associated-with-adverse-clinical-outcomes\/\"]}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.archimedlife.com\/#\/schema\/person\/28191618190aca02326147911e870968\",\"name\":\"Jake\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.archimedlife.com\/#personlogo\",\"inLanguage\":\"es\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/425a23ed2c54f443a5d7b0b81e7b51d6?s=96&d=mm&r=g\",\"caption\":\"Jake\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/posts\/7963"}],"collection":[{"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/comments?post=7963"}],"version-history":[{"count":0,"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/posts\/7963\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/media?parent=7963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/categories?post=7963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.archimedlife.com\/es\/wp-json\/wp\/v2\/tags?post=7963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}